Literature DB >> 2142949

Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radiocontrast infusion in chronic renal failure.

B R Kurnik1, L S Weisberg, I M Cuttler, P B Kurnik.   

Abstract

This study was performed to investigate the effects of atrial natriuretic peptide (ANP) and mannitol on renal blood flow (RBF) and radiocontrast-induced nephropathy (RCIN) in human subjects with chronic renal failure. ANP preserves glomerular filtration rate or RBF (or both) in severe animal models of acute renal failure. Radiocontrast is known to substantially decrease RBF and can induce acute renal failure. Twenty consecutive patients with chronic renal failure (60% with diabetes) were randomized in a prospective, double-blind fashion to receive either ANP (50 micrograms bolus, then 1 microgram/min infusion) or mannitol (15% at 100 ml/hr) for 2 hours before and during cardiac catheterization with diatrizoate. Baseline serum creatinine level (ANP 2.4 +/- 0.7 mg/dl, mannitol 2.5 +/- 0.8 mg/dl), medications, and quantity of radiocontrast were similar in both groups. Direct measurements of RBF were made with thermodilution catheters placed in the left renal vein. RBF rose significantly (p less than 0.05), to 198% of baseline at 15 minutes and 166% of baseline at 65 minutes in the group receiving ANP and remained stable in the group receiving mannitol. ANP levels rose significantly from baseline at 5, 15, 65 and 120 minutes in both groups (p less than 0.05). Acute renal failure defined as a 0.5 mg/dl rise of creatinine within 24 hours of cardiac catheterization, developed only in patients with diabetes mellitus and was similar in both experimental groups (ANP, 50%; mannitol, 30%). Only patients with diabetes mellitus responded with an increase in RBF after a 5-minute infusion of either ANP or mannitol (diabetes, 165% +/- 28% baseline; no diabetes, 96% +/- 8% baseline) (p less than 0.05). In conclusion, RBF was maintained or increased despite administration of radiocontrast, a documented renal vasoconstrictor. Patients with diabetes mellitus had a renal vasodilatory response to drug infusion. Acute renal failure occurred to a similar extent in both groups. Plasma ANP levels rose significantly in both groups. Mannitol may induce ANP release, thus contributing to mannitol's renal effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142949

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  11 in total

1.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2013-08       Impact factor: 2.801

2.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version. JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Jpn J Radiol       Date:  2013-08       Impact factor: 2.374

3.  Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial.

Authors:  Massimiliano Spaliviero; Nicholas E Power; Katie S Murray; Daniel D Sjoberg; Nicole E Benfante; Melanie L Bernstein; James Wren; Paul Russo; Jonathan A Coleman
Journal:  Eur Urol       Date:  2017-08-16       Impact factor: 20.096

Review 4.  Hormonal Regulation of Renal Fibrosis.

Authors:  Polina A Abramicheva; Egor Y Plotnikov
Journal:  Life (Basel)       Date:  2022-05-16

Review 5.  Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis.

Authors:  Sagar U Nigwekar; Sankar D Navaneethan; Chirag R Parikh; John K Hix
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 8.237

6.  Comparison of renal damage by iodinated contrast or gadolinium in an acute renal failure rat model based on serum creatinine levels and apoptosis degree.

Authors:  Hyo-Sung Kwak; Young-Hwan Lee; Young-Min Han; Gong-Yong Jin; Won Kim; Gyung-Ho Chung
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

7.  Effects of mannitol alone and mannitol plus furosemide on renal oxygen consumption, blood flow and glomerular filtration after cardiac surgery.

Authors:  Bengt Redfors; Kristina Swärd; Johan Sellgren; Sven-Erik Ricksten
Journal:  Intensive Care Med       Date:  2008-07-09       Impact factor: 17.440

Review 8.  Pharmacological strategies to prevent contrast-induced acute kidney injury.

Authors:  Pattharawin Pattharanitima; Adis Tasanarong
Journal:  Biomed Res Int       Date:  2014-02-26       Impact factor: 3.411

9.  Effectiveness of contrast-associated acute kidney injury prevention methods; a systematic review and network meta-analysis.

Authors:  Khalid Ahmed; Terri McVeigh; Raminta Cerneviciute; Sara Mohamed; Mohammad Tubassam; Mohammad Karim; Stewart Walsh
Journal:  BMC Nephrol       Date:  2018-11-13       Impact factor: 2.388

10.  Mannitol increases renal blood flow and maintains filtration fraction and oxygenation in postoperative acute kidney injury: a prospective interventional study.

Authors:  Gudrun Bragadottir; Bengt Redfors; Sven-Erik Ricksten
Journal:  Crit Care       Date:  2012-08-17       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.